IS7666A - N-súlfónýlpíperídín sem málmprótínkljúfatálmar (TACE) - Google Patents

N-súlfónýlpíperídín sem málmprótínkljúfatálmar (TACE)

Info

Publication number
IS7666A
IS7666A IS7666A IS7666A IS7666A IS 7666 A IS7666 A IS 7666A IS 7666 A IS7666 A IS 7666A IS 7666 A IS7666 A IS 7666A IS 7666 A IS7666 A IS 7666A
Authority
IS
Iceland
Prior art keywords
sulphonylpiperidine
tace
chelation
inhibitors
metal protein
Prior art date
Application number
IS7666A
Other languages
English (en)
Inventor
Nicholas Burrows Jeremy
Tucker Howard
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7666A publication Critical patent/IS7666A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IS7666A 2002-07-13 2005-01-26 N-súlfónýlpíperídín sem málmprótínkljúfatálmar (TACE) IS7666A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0216379.8A GB0216379D0 (en) 2002-07-13 2002-07-13 Compounds
PCT/GB2003/002959 WO2004006925A1 (en) 2002-07-13 2003-07-09 N-sulfonylpiperidines as metalloproteinase inhibitors (tace)

Publications (1)

Publication Number Publication Date
IS7666A true IS7666A (is) 2005-01-26

Family

ID=9940460

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7666A IS7666A (is) 2002-07-13 2005-01-26 N-súlfónýlpíperídín sem málmprótínkljúfatálmar (TACE)

Country Status (16)

Country Link
US (1) US20060142336A1 (is)
EP (1) EP1534281A1 (is)
JP (1) JP2005536501A (is)
CN (1) CN1681504A (is)
AU (1) AU2003254436A1 (is)
BR (1) BR0312614A (is)
CA (1) CA2492083A1 (is)
GB (1) GB0216379D0 (is)
IL (1) IL166009A0 (is)
IS (1) IS7666A (is)
MX (1) MXPA05000518A (is)
NO (1) NO20050765L (is)
PL (1) PL375304A1 (is)
RU (1) RU2004138547A (is)
WO (1) WO2004006925A1 (is)
ZA (1) ZA200500209B (is)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1431285B1 (en) 2001-09-07 2009-01-07 Kaken Pharmaceutical Co., Ltd. Reverse hydroxamic acid derivatives
BRPI0910034B1 (pt) 2008-03-25 2022-02-08 Affectis Pharmaceuticals Ag Antagonistas do p2x7r e composições farmacêuticas que os compreendem
AU2010237302A1 (en) 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
US20240174654A1 (en) * 2021-03-01 2024-05-30 Orion Corporation Process for the preparation of a cyp11a1 inhibitor and intermediates thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2333554A1 (en) * 1998-06-17 1999-12-23 Chu-Baio Xue Cyclic hydroxamic acids as metalloproteinase inhibitors
US6479502B1 (en) * 1998-08-29 2002-11-12 British Biotech Pharmaceuticals Hydroxamic acid derivatives as proteinase inhibitors
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
US6358980B1 (en) * 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors

Also Published As

Publication number Publication date
IL166009A0 (en) 2006-01-15
PL375304A1 (en) 2005-11-28
CN1681504A (zh) 2005-10-12
MXPA05000518A (es) 2005-03-23
ZA200500209B (en) 2005-11-02
NO20050765L (no) 2005-04-13
GB0216379D0 (en) 2002-08-21
US20060142336A1 (en) 2006-06-29
BR0312614A (pt) 2005-05-10
AU2003254436A1 (en) 2004-02-02
CA2492083A1 (en) 2004-01-22
RU2004138547A (ru) 2005-08-20
WO2004006925A1 (en) 2004-01-22
JP2005536501A (ja) 2005-12-02
EP1534281A1 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
IS7792A (is) Hýdantóínafleiður og notkun þeirra sem TACE hemla
DE60320933D1 (de) Rho-kinase inhibitoren
IS7717A (is) Pýrídasínónafleiður sem PDF4-hemlar
DK1534290T3 (da) Hidtil ukendte kinasehæmmere
EP1499336A4 (en) PROTEASE INHIBITORS
DE60211317D1 (de) Rho-kinase inhibitoren
DE60218138D1 (de) Rho-kinase inhibitoren
EG25482A (en) Inhibitors
NO20034042D0 (no) Metallproteinase-inhibitorer
IS7509A (is) Þíoxantínafleiður sem mergperoxídasatálmar
DK1560584T3 (da) Fab I inhibitorer
EP1549316A4 (en) HAMMER OF TFGbeta
DE602004018837D1 (de) Ptidase-iv-inhibitoren
SI2594265T1 (sl) CA-IX specifični inhibitorji
NO20034032D0 (no) Metallproteinase-inhibitorer
DE60324208D1 (de) Biarylsulfonamide als mmp-inhibitoren
ITMI20021399A0 (it) Inibitori della cicloossigenasi 2
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
DK1501804T3 (da) Isoquinolinderivat MAO-B-inhibitorer
NO20034109D0 (no) Parafininhibitor-komposisjon
IS7666A (is) N-súlfónýlpíperídín sem málmprótínkljúfatálmar (TACE)
EP1531857A4 (en) Metalloproteinase inhibitors
NO20013535L (no) Nöytrofil-funksjons-inhibitorer
ATE373648T1 (de) Nf-kappab-inhibitoren
AU2003242559A8 (en) Alkylaminosiloxanes as corrosion inhibitors